Empasiburbart for MMN: Clinical Update & Biomarker Strategy
Time: 4:30 pm
day: Conference Day One
Details:
- Outlining a comprehensive clinical update on Empasiprubart’s performance in treating MMN, including key efficacy data, patient outcomes, and safety profile from ongoing trials
- Detailing the specific biomarker strategy employed in Empasiprubart trials for MMN, highlighting how these markers are used to assess disease activity, predict treatment response, and monitor therapeutic impact
- Exploring the implications of the biomarker strategy for future clinical practice, discussing how these insights could lead to more precise patient selection, personalized dosing, and improved long-term management of MMN
